Clinical Trial Search

Primary: Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery. — 34; 11; 41; 24 percentage of cases

Primary: Number of Participants That Received Rescue Medication for Withdrawal Symptoms Within 1 Hour — 9; 19 Participants

Primary: Change in the Total Atheroma Volume From Baseline to 12 Weeks — -7.63; -3.10 mm^3 — p=0.2533

Primary: Number of Participants With Adverse Events (AEs) — 136 Participants

Primary: Total Combined Score (TCS) During the Peak Ragweed Season (RS) — 4.39; 7.12 Score on a scale — p=< 0.001

Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 68; 25 Participants — p=<0.001

Primary: Time to AVF Primary Unassisted Patency — 214; 171 Days — p=0.254

Primary: Mid Facial Mucosal Level at Implant Site — 0.36; 0.49 mm

Primary: Number of Participants in Clinical Remission on Canakinumab Who Are Able to Remain at an Initial Reduced Canakinumab Dose or Prolonged Canakinumab Dose Interval. — 27…

Primary: Total Time From Admission to Delivery — 13.5; 12.4 hours — p=0.38

Primary: Time to Delivery — 28.1; 20.1 hours — p=0.663

Primary: Incidence Rate of Stroke and Systemic Embolism (SE) — 2.898; 3.563 per patient-year

Primary: Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings — 130; 158 Participants — p=0.015

Primary: Number of Patients With Physician's Global Assessment (sPGA) Score 0 or 1 — 24 Participants

Primary: PP1- Serum IGF-1 Levels, DXA, Resting Metabolic Rate, Total Body Water, 3-D Echo, Cardiac MRI, Dobutamine Stress Echocardiogram, Ergometry, General Health Assessment…